Company

Life Biosciences

Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

What it is

Life Biosciences (founded 2017) is a holding company spawning operating subsidiaries focused on different mechanisms of aging:

Cellular reprogramming (now the main programme).
Senescence (early on).
Mitochondrial focus.
Stem-cell biology.

Current focus

Partial Yamanaka-factor reprogramming via AAV gene therapy. Lead programmes in vision restoration (glaucoma, non-arteritic anterior ischaemic optic neuropathy / NAION) building on David Sinclair’s 2020 Nature paper showing OSK restored vision in mouse glaucoma.

Pipeline state

Pre-clinical to early-clinical. First-in-human trials planned in ophthalmology indications where local AAV delivery has favourable risk-benefit and where Sinclair’s mouse work showed clear effects.

Notable

David Sinclair on scientific advisory board / co-founder.
Has spun out and consolidated multiple subsidiaries over its history.